
ãã¡ã€ã¶ãŒç€Ÿè£œæ³šå°å€ã®mRNAãããã®DNAã«é転åãããããšãç€ºãæ°ããªç ç©¶çµæãçºè¡šããã
BYARJUN WALIAÂ MARCH 3, 2022
ã¹ãŠã§ãŒãã³ã§è¡ãããæè¿ã®ç ç©¶ã§ããã¡ã€ã¶ãŒç€Ÿã®COVIDã¯ã¯ãã³ã«å«ãŸããmRNAããããã®DNAã«é転åãããããšã瀺ã蚌æ ãçºè¡šãããŸããããã®ç ç©¶ã¯ã€ã³ãããã§è¡ãããããã®èçŽ°èæ ªãçšããŠè¡ããããããã¯ãHIVãä»ã®ã¬ãããŠã€ã«ã¹ãè¡ã£ãŠããããã«ãç åäœããã®éºäŒã³ãŒãããããã¯ãã®äžéšãããã²ãã ã«çµ±åããããšã瀺åããŠãããããŸã å€ãã®æªè§£æ±ºã®çåãæ®ã£ãŠããã
éåžžãDNAã¯RNAã«è»¢åãŸãã¯ã³ããŒããããã®åŸã¿ã³ãã¯è³ªã«ç¿»èš³ããããé転åé µçŽ ã¯ãRNAãDNAã«ã³ããŒããŠæ»ãããã®ãããªæŽ»åã¯ããŠã€ã«ã¹ãæ©èœããããã«å¿ èŠã§ããããŠã€ã«ã¹ã®å Žåãé転åé µçŽ ã«ãã£ãŠããŠã€ã«ã¹ã¯ãã®DNAã宿䞻现èã®DNAã«æ¿å ¥ãã现èã«ãã£ãšå€ãã®ãŠã€ã«ã¹ãäœãããããšãã§ããããã«ãªããŸããããã¯ããŠã€ã«ã¹ã«ãšã£ãŠã¯è¯ãããšã ãã宿䞻ã«ãšã£ãŠã¯æªãããšã§ããã
2012幎ã«ãVirus, Essential Agents of Lifeãã«æ²èŒãããè«æã§ã¯ããã説æãããŠããã
"ãŠã€ã«ã¹ã®äžã«ã¯ã现èã«ææãããšããã®ã©ã€ããµã€ã¯ã«ã®äžéšãšããŠïŒã¬ãããŠã€ã«ã¹ãªã©ïŒããããã¯å¶çºçã«ãå®¿äž»ã®æè²äœã«ã²ãã ãçµã¿èŸŒããã®ããããŸãããŠã€ã«ã¹ã®ã²ãã çµ±åã¯ã现èå ãžã®ãŠã€ã«ã¹ã®é·æçãªæç¶ãä¿é²ããå¯èœæ§ãããäžæ¹ã§ãéºäŒåç Žå£ãæ¿å ¥åå€ç°èªçºãçŽ°èæ»ãªã©ã宿䞻现èã«åçãªçµæããããããããã«çš®ã®é²åã«ãå¯äžããå¯èœæ§ããããŸãã"
ããããå¿ ãããæªãããšã°ããã§ã¯ãªããããããŸããã誰ã«ãããããªãããšã§ããããŠã€ã«ã¹ã¯ç§ãã¡ã®ã²ãã ã®å€§éšåãå ããŠãããç§ãã¡ã®å éšã«ã¯å€ä»£ã®ç¥å ãDNAã«è»¢åãããŠã€ã«ã¹ãååšããŠããŸããéå»ããã²ãã ã«çµã¿èŸŒãŸãããããã®ãŠã€ã«ã¹ã®äžã«ã¯ãç§ãã¡ãå®ã£ãŠããããã®ãããã°ãç§ãã¡ãå·ã€ããäŸãã°çã®ãããªæ§ã ãªç æ°ã®ãªã¹ã¯ãé«ãããã®ããããããããŸããããããã話ããããŸããããCOVIDã®èªç¶ææã§ãããªã£ãå ŽåãšãäŸãã°ã¯ã¯ãã³ã§èªå°ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãç§ãã¡ã®çްèãäœãããã«æç€ºãããå Žåãšã§ãéãããããšããã°ãããã¯äœãªã®ããç¥ãããšã¯å°é£ã§ãã
æžå¿µãããã®ã¯ãéºäŒåããŒã¹ã®ã¯ã¯ãã³ã«ããmRNAååãã现èå ã§ããå®å®ã«ãªãããã«æå³çã«æäœãããŠããç¹ã§ããããœã€ããŠãªãžã³ããšããååãmRNAã«ä»å ãããéåžžã®mRNAãããåæžæãé·ããªã£ãŠããã®ã§ãããããã£ãŠã现èå ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çç£ã忢ãããããšã¯ãªãã®ã§ãããã®ããšã®æå³ãããšããã¯ããããŸããã
ãã®ç ç©¶ã®åæ©ã¯ãè«æã«ããããã«ãç ç©¶è ã®ãµã€ãã§ãããã¡ã€ã¶ãŒç€Ÿã欧å·å»è¬ååºïŒEMAïŒã«æäŸããè¬ç©åæ ããŒã¿ã ã£ãããã ãæ¥æ¬æ¿åºããã®çäœå ååžããŒã¿ãå ¬éããã
mRNAè質ããç²åã¯ãã¯ã¯ãã³å 容ç©ã®äžéšãèèïŒ18%ïŒãã¯ãããäœå ã®æ§ã ãªèåšã«å°éããããšã瀺ãããŸããããã®ãããã¹ãŠã§ãŒãã³ã®ç ç©¶è ãã¡ã¯ããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãããã®è现èã«äžãã圱é¿ã調ã¹ãããšã«ããã®ã§ããã
èè ãã«ããã°
"ãŸããBNT162b2ã®mRNAã¯ãBNT162b2æé²åŸã6æéãšããéãã§çްèå ã§DNAã«é転åãããããšã瀺ããŠããã"
ä»åã®ç ç©¶ã¯ãæšå¹Ž5æã«çºè¡šããããCOVIDã®èªç¶ææããåŸãRNAãå¹é€ãã现èã®ã²ãã ã«éç©ããæ£è ç±æ¥ã®çµç¹ã§çºçŸããããšã瀺ããå è¡ç ç©¶ã®åŸã«è¡ããããã®ã§ãããããã£ãŠãç ç©¶è ããã®ããšãã¯ã¯ãã³ã«é¢ããŠãåœãŠã¯ãŸããã©ããã調ã¹ãããšããçç±ã¯çè§£ã§ããªãããªãã
ãããã®ç¥èŠã¯ããéœæ§ããšå€å®ããã人ã®å€ããå®éã«ã¯ææããŠããªãå¯èœæ§ãããããšã®èª¬æã«ããªããããããªãããã®æ€æ»ã¯ãåã«ããã®ã²ãã ã«çµã¿èŸŒãŸãããŠã€ã«ã¹ã®äžéšãæŸã£ãŠããã ããªã®ãããããªããPCRæ³ã¯ãæææ§ãŠã€ã«ã¹ã§ã¯ãªããã²ãã ã«çµã¿èŸŒãŸãããŠã€ã«ã¹ã®DNAé åã«ç±æ¥ãããŠã€ã«ã¹è»¢åç©ãæ€åºããã®ãããããªãã
èè ãã¯ããã®çµæã説æããç¹°ãè¿ããŠããã
"ãã®çµæãBNT162b2 mRNAã¯å±ææ³šå°éšäœæ¿åºŠã®0.5ïŒ ã«çžåœããæ¿åºŠïŒ0.5ÎŒg/mLïŒã§Huh7现èã«å®¹æã«å ¥ããLINE-1éºäŒåããã³ã¿ã³ãã¯è³ªçºçŸã®å€åãèªçºãã6æé以å ã«BNT162b2ã®é転åãæ€åºã§ããããšãããããŸããã"
LINE-1ã¬ãããã©ã³ã¹ããžã·ã§ã³ã¯ããããã²ãã äžå®å®æ§/DNAæå·ã®äž»èŠãªç¹åŸŽã§ãããFrontiers in Cell Development and Biologyã«æ²èŒãããç·èª¬ã§èª¬æãããŠããŸãã
"LINE-1ã®å¹ççãªã¬ãããã©ã³ã¹ããžã·ã§ã³ã¯ããã°ãã°çްèåšæãæç³žåè£äžã®æ žèç Žå£[52,53]ããŸã倿¥æ§ã¬ãããŠã€ã«ã¹[54,55]ãšé¢é£ããŠãããLINE-1ã®æ žãžã®äŸµå ¥ãä¿é²ãã".
LINE-1ãšã¬ã¡ã³ãã¯å€ä»£ã®ã¬ãããŠã€ã«ã¹ææã®åæ®ã§ãããã²ãã ã®çŽ17ïŒ ãå ããŠãããããã§èµ·ããããšã¯ã人éã®å¥åº·ã«æ§ã ãªåœ¢ã§è²¢ç®ãããã劚ãã«ãªã£ããããããšããããŸãã
2021幎10æã«çºè¡šãããç ç©¶ã§ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãå®éšå®€ã®çŽ°èæ ªã§ãDNAæå·ä¿®åŸ©ãèããé»å®³ãããããšã瀺ãããŠããã®ã¯æ³šç®ã«å€ããã
ããã«ãäžèšã®çäœå ååžããŒã¿ã¯ãããã§ãå©çšå¯èœã§ããããç ç©¶ã§ã¯ãã¢ããmRNAã¯ã¯ãã³ã®æ¥çš®åŸã13人ã®åå è ã®ãã¡11人ã®è¡æ¶²äžã«ã¹ãã€ã¯ãããã€ã³ãæ€åºãããããšã瀺ãããŸããã
ã¹ãŠã§ãŒãã³ã®ç ç©¶ã®èè ã¯ã"ã¯ã¯ãã³é¢é£ã®å¯äœçšã®åºç€ãšãªãã¡ã«ããºã ãããããçè§£ããããã«ã¯ã现èããã³ååè§£æã ãã§ãªããèšåºèª¿æ»ãå¿ èŠã§ã "ãšèª¬æããŠããŸãã
ãããããã®ãããªç ç©¶ã¯ããªãããã»ã©å€ãã®COVIDã¯ã¯ãã³ã«ããå·å®³ãå ±åãããŠããã®ãããã®æ ¹æ¬çãªã¡ã«ããºã ã®ããã€ãã説æããã®ã«åœ¹ç«ã€ãšæããŸãã
ç§ã¯æè¿ãã¹ãã€ã¯ã¿ã³ãã¯è³ªããæ¯æ§ããæã€ãã©ããããŸããéºäŒåããŒã¹ã®ã¯ã¯ãã³ã现èã«äœãããæç€ºããã¹ãã€ã¯ã¿ã³ãã¯è³ªãšå€©ç¶ããŒãžã§ã³ãšã®éã«ã©ã®ãããªéãããããã«ã€ããŠè«ããèšäºãçºè¡šããŸããããã®èšäºã§ã¯ã现èã®å®å šæ§ã«é¢ããæžå¿µããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çæã®çµæã现èå ã§èµ·ãã£ãŠããããšãæ žã«åœ±é¿ãäžãããã©ããã«ã€ããŠãè§ŠããŠããŸãã
ãã®åéã®å°éå®¶ã®éã§ã¯ãçãã®ãªãçåããããããããŸããç§ã¯ãå°ãªããšãèªåã衚çŸããæ¢æ±ãã質åããæ©äŒãäžããŠãããããšã«æè¬ããŠããŸãã